XLO · Xilio Therapeutics, Inc.
$9.13
-0.02 (-0.22%)
At close · Jul 29
Market Cap
$52.91M
Shares
5.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$43.77M
+589.9%
FY2025
Net Income
-$35.04M
+39.8%
FY2025
Operating Margin
-95.92%
+859pp
FY2025
Diluted EPS
-$4.19
+72.5%
FY2025
Operating Cash Flow
-$4.99M
+72.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $53.48M | $43.77M | $6.34M | — | — | — | — | |
| $67.61M | $56.04M | $41.21M | $52.14M | $59.2M | $51.19M | $43.91M | |
| $28.12M | $29.71M | $24.78M | $27M | $29.95M | $23.86M | $10.65M | |
| — | $1.54M | $1.64M | $1.9M | $1.85M | $1.5M | $1.07M | |
| — | — | $937K | — | — | — | — | |
| $95.73M | $85.75M | $66.93M | $79.13M | $89.15M | $75.04M | $54.56M | |
| -$42.24M | -$41.98M | -$60.58M | -$79.13M | -$89.15M | -$75.04M | -$54.56M | |
| — | -95.92% | -954.95% | — | — | — | — | |
| — | -$40.44M | -$58.94M | -$77.23M | -$87.3M | -$73.55M | -$53.5M | |
| $10.94M | $6.95M | $2.34M | $2.73M | $927K | -$756K | -$656K | |
| — | -$35.04M | -$58.24M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$31.3M | -$35.04M | -$58.24M | -$76.4M | -$88.22M | -$75.8M | -$55.22M | |
| — | -80.05% | -918.05% | — | — | — | — | |
| -$31.3M | -$35.04M | -$58.24M | -$76.4M | -$88.22M | -$75.8M | -$55.22M | |
| USD/shares | — | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 | -$1,475.88 |
| USD/shares | — | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 | -$1,475.88 |
| shares | — | 8.36M | 3.82M | 1.96M | 1.96M | 400.45K | 37.41K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.79×
EV/EBIT
—
Peer median 40.58×
P/E (TTM)
—
Peer median 1.60×
Peer medians compare against the 291 similar-size Biotechnology companies (of 522 listed).